| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-2157 | |
| Phytochemical name or plant extracts | Lobeline | |
| PMID | 18222670 | |
| Literature evidence | Lobeline, a piperidine alkaloid from Lobelia inflata and several other Lobelia species, inhibited P-gp activity. | |
| IUPAC name | 2-[(2R,6S)-6-[(2S)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl]-1-phenylethanone | |
| Phytochemicals’ class or type of plant extracts | Piperidine alkaloid | |
| Source of phytochemicals or plant Extracts | Lobelia inflata | |
| Geographical availability | Alabama, Arkansas, Connecticut, Delaware, Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nebraska, New Brunswick, New Hampshire, New Jersey, New York, North Carolina, Nova Scotia, Ohio, Oklahoma, Ontario, Pennsylvania, Prince Edward I., Québec, Rhode I., South Carolina, Tennessee, Vermont, Virginia, West Virginia, Wisconsin | |
| Plant parts | NA | |
| Other cancers | Breast cancer, Colon cancer, Leukemia | |
| Target gene or protein | P-gp | |
| Gene or Protein evidence | Lobeline, a piperidine alkaloid from Lobelia inflata and several other Lobelia species, inhibited P-gp activity. | |
| Target pathways | NA | |
| IC50 | NA | |
| Potency | However, lobeline cannot block BCRP (Breast Cancer Resistance Protein) dependent mitoxantrone efflux. Lobeline could be a good candidate for the development of new MDR reversal agents. | |
| Cell line/ mice model | Caco-2, CCRF-CEM, MDA-MB-231pcDNA3-BCRP-clone23 | |
| Additional information | NA | |
| PubChem ID | 101616 | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:143415-1 | |
| Safety | NA |